Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Nov;22(11):1531.
doi: 10.1016/S1473-3099(22)00592-8. Epub 2022 Sep 26.

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic

Russell M Nichols  1 , Carmen Deveau  2 , Himanshu Upadhyaya  2
Affiliations
Comment

Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic

Russell M Nichols et al. Lancet Infect Dis. 2022 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

RMN, CD, and HU are salaried employees and stockholders of Eli Lilly and Company.

Comment on

References

    1. Hentzien M, Autran B, Piroth L, Yazdanpanah Y, Calmy A. A monoclonal antibody stands out against omicron subvariants: a call to action for a wider access to bebtelovimab. Lancet Infect Dis. 2022;22 - PMC - PubMed
    1. APM News Lilly n'envisage toujours aucun accès au bebtélovimab en Europe (DGS) July 20, 2022. https://www.apmnews.com/nostory.php?objet=385138
    1. Dougan M, Azizad M, Chen P, et al. Bebtelovimab, alone or together with bamlanivimab and etesevimab, as a broadly neutralizing monoclonal antibody treatment for mild to moderate, ambulatory COVID-19. medRxiv. 2022 published online March 12 (preprint).
    1. Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021;21:382–393. - PMC - PubMed
    1. FDA Bebtelovimab letter of authorization. Aug 5, 2022. https://www.fda.gov/media/156151/download